Global PEGylated Drugs Market Research Report—Forecast till 2025
出 版 商：Market Research Future
出版日期：2020/12/01
頁 數：103頁
文件格式：PDF
價 格：
USD 4,450 (Single-User License)
USD 6,250 (Global-User License)
USD 6,250 (Global-User License)
Global PEGylated Drugs Market: Information by Molecule (Protein, FAB’ Fragment, Enzyme and Aptamer), by Indication (Cancer, Gout, Hemophilia and Hepatitis) and by Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2025
Market Analysis
PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to enhance therapeutic effectiveness of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings. The major companies are strictly investing in R&D of PEGylated drugs and have good number of molecules in the pipeline. So for example, UCB and Biogen are assessing safety and effectiveness of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is developed for the treatment of systemic lupus erythematosus. However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period. The Global PEGylated Drugs Market is rising due to the growth in the spread of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. So for example, according to data from the National Cancer Institute, in the year 2016, 15.5 million new cases of cancer have been registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer creates a demand for effective drugs. Usage of advanced drug delivery system with PEGylation technology is important in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to increase growth of the global PEGylated drugs market. PEGylated Drugs Market is forecast to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.
Market Segmentation
The Global PEGylated Drugs Market has been segmented by Molecule, Indication and region. By Molecule The Global PEGylated Drugs Market has been segmented into Protein, FAB’ Fragment, Enzyme and Aptamer. PEGylated protein is anticipated to account for the leading market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. Global PEGylated Drugs Market has been divided by Indication into Cancer, Gout, Hemophilia and Hepatitis. Geographically, the Global PEGylated Drugs Market has been split into regions like North America (US & Canada), Latin America, Europe (Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East & Africa.
Regional Analysis
Geographically, The Global PEGylated Drugs Market is broadly segmented into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is responsible for a market share of 65.73% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest Global PEGylated Drugs Market in the year 2018. The increasing efforts by the government to decrease persistent disease burden owing to the mounting occurrence of cancer in the region is estimated to push the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market. The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.
Major Players
Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG are some of the prominent players in The Global PEGylated Drugs Market. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets. Some of the projected onlooker for the global PEGylated Drugs Market are Academic research institutes, Pharmaceutical companies, Biotechnology Companies, PEGylation products manufacturing companies, Contract research organizations (CROs) and Market research & consulting firms.
Market Analysis
PEGylation refers to the process of covalent and non-covalent attachment of polyethylene glycol polymer chains to bioactive molecules (proteins, peptides, enzymes, antibody fragments, oligonucleotides, etc.). It is a promising technique to enhance therapeutic effectiveness of medicines in clinical settings. Several PEGylated drugs have been approved by the Food and Drug Administration (FDA), and many drugs are being tested in clinical settings. The major companies are strictly investing in R&D of PEGylated drugs and have good number of molecules in the pipeline. So for example, UCB and Biogen are assessing safety and effectiveness of dapirolizumab pegol. Dapirolizumab pegol is an anti-CD40L pegylated Fab and is in Phase 2b of the clinical trial. The drug is developed for the treatment of systemic lupus erythematosus. However, adverse reactions associated with PEGylated drugs and drug recalls are anticipated to restrain the growth of the global PEGylated drugs market during the forecast period. The Global PEGylated Drugs Market is rising due to the growth in the spread of chronic diseases such as cancer, growing pharmaceutical industry, and advancements in the biologics sector. So for example, according to data from the National Cancer Institute, in the year 2016, 15.5 million new cases of cancer have been registered, and approximately USD 147.3 billion were spent for cancer care in the US. This rising prevalence of cancer creates a demand for effective drugs. Usage of advanced drug delivery system with PEGylation technology is important in the field of anti-cancer therapy as PEGylating enhances retention time of therapeutics which in turn is expected to increase growth of the global PEGylated drugs market. PEGylated Drugs Market is forecast to register a CAGR of 5.53% to reach USD 13,503.67 Million by 2025.
Market Segmentation
The Global PEGylated Drugs Market has been segmented by Molecule, Indication and region. By Molecule The Global PEGylated Drugs Market has been segmented into Protein, FAB’ Fragment, Enzyme and Aptamer. PEGylated protein is anticipated to account for the leading market share of 64.80% during the forecast period. Rising demand for PEGylation, increase in a number of chronic diseases including cancer, and product launches by major market players are propelling the growth of this segment. Global PEGylated Drugs Market has been divided by Indication into Cancer, Gout, Hemophilia and Hepatitis. Geographically, the Global PEGylated Drugs Market has been split into regions like North America (US & Canada), Latin America, Europe (Germany, UK, France, Spain, Italy and Rest of Europe), Asia-Pacific (China, India, Japan, Australia & New Zealand, Southeast Asia and Rest of Asia-Pacific), Middle East & Africa.
Regional Analysis
Geographically, The Global PEGylated Drugs Market is broadly segmented into different regions like Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is responsible for a market share of 65.73% in the year 2018. Americas is sub-segmented into North America and South America. North America has been further sub-segmented into the US and Canada. Europe was the second-largest Global PEGylated Drugs Market in the year 2018. The increasing efforts by the government to decrease persistent disease burden owing to the mounting occurrence of cancer in the region is estimated to push the market growth. The Europe region is further segmented into Western Europe and Eastern Europe. Western Europe, on the basis of countries has been, segmented into Germany, the UK, France, Italy, Spain, and the rest of Western Europe. The Asia-Pacific region has been categorized as China, India, Japan, Australia, South Korea and the rest of Asia-Pacific. It holds the third-largest position in the PEGylated drugs market. The Middle East & Africa is expected to witness a remarkable growth owing to the increasing applications PEGylated drugs for the treatment of chronic diseases.
Major Players
Horizon Therapeutics Plc, F. Hoffmann-La Roche Ltd., Pfizer Inc., Novo Nordisk A/S, UCB S.A., Amgen, Inc., AstraZeneca, Merck & Co., Inc., Takeda Pharmaceutical Company Limited, and Bayer AG are some of the prominent players in The Global PEGylated Drugs Market. The players operating in the global PEGylated Drugs Market are focusing on product launches, along with expanding their global footprints by entering untapped markets. Some of the projected onlooker for the global PEGylated Drugs Market are Academic research institutes, Pharmaceutical companies, Biotechnology Companies, PEGylation products manufacturing companies, Contract research organizations (CROs) and Market research & consulting firms.
TABLE OF CONTENTS
1 EXECUTIVE SUMMARY
1.1 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 14
1.2 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 15
2 Market Introduction
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 RESEARCH OBJECTIVE 16
2.4 MARKET STRUCTURE 17
3 Research Methodology
3.1 RESEARCH PROCESS 18
3.2 PRIMARY RESEARCH 19
3.3 SECONDARY RESEARCH 20
3.4 MARKET SIZE ESTIMATION 21
3.5 FORECAST MODEL 22
3.6 LIST OF ASSUMPTIONS 23
4 MARKET DYNAMICS
4.1 INTRODUCTION 24
4.2 DRIVERS 25
4.2.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS CANCER 25
4.2.2 GROWING PHARMACEUTICAL INDUSTRY 25
4.2.3 ADVANCEMENT IN THE BIOLOGICS SECTOR 25
4.3 RESTRAINTS 26
4.3.1 ADVERSE DRUG REACTIONS ASSOCIATED WITH PEGYLATED DRUGS 26
4.3.2 DRUG RECALL 26
4.4 OPPORTUNITIES 26
4.4.1 STRONG PIPELINE FOR PEGYLATED DRUGS 26
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 27
5.1.1 R&D 28
5.1.2 MANUFACTURING 28
5.1.3 DISTRIBUTION & SALES 28
5.1.4 POST-SALES MONITORING 28
5.2 PORTER’S FIVE FORCES MODEL 29
5.2.1 THREAT OF NEW ENTRANTS 30
5.2.2 BARGAINING POWER OF SUPPLIERS 30
5.2.3 BARGAINING POWER OF BUYERS 30
5.2.4 THREAT OF SUBSTITUTES 30
5.2.5 INTENSITY OF RIVALRY 30
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE
6.1 OVERVIEW 31
6.2 PROTEIN 33
6.3 FAB’ FRAGMENT 33
6.4 ENZYME 34
6.5 APTAMER 34
7 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION
7.1 OVERVIEW 35
7.2 CANCER 37
7.3 GOUT 37
7.4 HEMOPHILIA 38
7.5 HEPATITIS 38
8 GLOBAL PEGYLATED DRUGS MARKET, BY REGION
8.1 OVERVIEW 39
8.2 AMERICAs 41
8.2.1 NORTH AMERICA 43
8.2.2 LATIN AMERICA 45
8.3 EUROPE 46
8.3.1 WESTERN EUROPE 48
8.3.2 EASTERN EUROPE 55
8.4 ASIA-PACIFIC 56
8.4.1 JAPAN 58
8.4.2 CHINA 59
8.4.3 INDIA 60
8.4.4 AUSTRALIA 61
8.4.5 SOUTH KOREA 62
8.4.6 REST OF ASIA-PACIFIC 63
8.5 MIDDLE EAST & AFRICA 64
8.5.1 MIDDLE EAST 66
8.5.2 AFRICA 67
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION 68
9.2 MAJOR PEGYLATED DRUGS 70
10 COMPANY PROFILES
10.1 HORIZON THERAPEUTICS PLC 71
10.1.1 COMPANY OVERVIEW 71
10.1.2 FINANCIAL OVERVIEW 71
10.1.3 PRODUCTS/SERVICES OFFERED 72
10.1.4 KEY DEVELOPMENTS 72
10.1.5 SWOT ANALYSIS 73
10.1.6 KEY STRATEGIES 73
10.2 F. HOFFMANN-LA ROCHE LTD 74
10.2.1 COMPANY OVERVIEW 74
10.2.2 FINANCIAL OVERVIEW 74
10.2.3 PRODUCTS/SERVICES OFFERED 75
10.2.4 KEY DEVELOPMENTS 75
10.2.5 SWOT ANALYSIS 75
10.2.6 KEY STRATEGIES 76
10.3 PFIZER INC. 77
10.3.1 COMPANY OVERVIEW 77
10.3.2 FINANCIAL OVERVIEW 77
10.3.3 PRODUCTS/SERVICES OFFERED 78
10.3.4 KEY DEVELOPMENTS 78
10.3.5 SWOT ANALYSIS 79
10.3.6 KEY STRATEGIES 79
10.4 NOVO NORDISK A/S 80
10.4.1 COMPANY OVERVIEW 80
10.4.2 FINANCIAL OVERVIEW 80
10.4.3 PRODUCTS/SERVICES OFFERED 81
10.4.4 KEY DEVELOPMENTS 81
10.4.5 SWOT ANALYSIS 82
10.4.6 KEY STRATEGIES 82
10.5 UCB S.A. 83
10.5.1 COMPANY OVERVIEW 83
10.5.2 FINANCIAL OVERVIEW 83
10.5.3 PRODUCTS/SERVICES OFFERED 84
10.5.4 KEY DEVELOPMENTS 84
10.5.5 SWOT ANALYSIS 85
10.5.6 KEY STRATEGIES 85
10.6 AMGEN, INC. 86
10.6.1 COMPANY OVERVIEW 86
10.6.2 FINANCIAL OVERVIEW 86
10.6.3 Products/Services Offered 87
10.6.4 KEY DEVELOPMENTS 87
10.6.5 KEY STRATEGIES 88
10.7 ASTRAZENECA 89
10.7.1 COMPANY OVERVIEW 89
10.7.2 FINANCIAL OVERVIEW 89
10.7.3 PRODUCTS/SERVICES OFFERED 90
10.7.4 KEY DEVELOPMENTS 90
10.7.5 SWOT ANALYSIS 90
10.7.6 KEY STRATEGIES 91
10.8 MERCK & CO., INC. 92
10.8.1 COMPANY OVERVIEW 92
10.8.2 FINANCIAL OVERVIEW 92
10.8.3 PRODUCTS/SERVICES OFFERED 93
10.8.4 KEY DEVELOPMENTS 93
10.8.5 SWOT ANALYSIS 94
10.8.6 KEY STRATEGIES 94
10.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 95
10.9.1 COMPANY OVERVIEW 95
10.9.2 FINANCIAL OVERVIEW 95
10.9.3 PRODUCTS/SERVICES OFFERED 96
10.9.4 KEY DEVELOPMENTS 96
10.9.5 SWOT ANALYSIS 96
10.9.6 KEY STRATEGIES 97
10.10 BAYER AG 98
10.10.1 COMPANY OVERVIEW 98
10.10.2 FINANCIAL OVERVIEW 98
10.10.3 PRODUCTS/SERVICES OFFERED 99
10.10.4 KEY DEVELOPMENTS 99
10.10.5 SWOT ANALYSIS 99
10.10.6 KEY STRATEGIES 100
11 APPENDIX
11.1 REFERENCES 101
11.2 RELATED REPORTS 101
1 EXECUTIVE SUMMARY
1.1 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE 14
1.2 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION 15
2 Market Introduction
2.1 DEFINITION 16
2.2 SCOPE OF THE STUDY 16
2.3 RESEARCH OBJECTIVE 16
2.4 MARKET STRUCTURE 17
3 Research Methodology
3.1 RESEARCH PROCESS 18
3.2 PRIMARY RESEARCH 19
3.3 SECONDARY RESEARCH 20
3.4 MARKET SIZE ESTIMATION 21
3.5 FORECAST MODEL 22
3.6 LIST OF ASSUMPTIONS 23
4 MARKET DYNAMICS
4.1 INTRODUCTION 24
4.2 DRIVERS 25
4.2.1 INCREASE IN THE PREVALENCE OF CHRONIC DISEASES SUCH AS CANCER 25
4.2.2 GROWING PHARMACEUTICAL INDUSTRY 25
4.2.3 ADVANCEMENT IN THE BIOLOGICS SECTOR 25
4.3 RESTRAINTS 26
4.3.1 ADVERSE DRUG REACTIONS ASSOCIATED WITH PEGYLATED DRUGS 26
4.3.2 DRUG RECALL 26
4.4 OPPORTUNITIES 26
4.4.1 STRONG PIPELINE FOR PEGYLATED DRUGS 26
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 27
5.1.1 R&D 28
5.1.2 MANUFACTURING 28
5.1.3 DISTRIBUTION & SALES 28
5.1.4 POST-SALES MONITORING 28
5.2 PORTER’S FIVE FORCES MODEL 29
5.2.1 THREAT OF NEW ENTRANTS 30
5.2.2 BARGAINING POWER OF SUPPLIERS 30
5.2.3 BARGAINING POWER OF BUYERS 30
5.2.4 THREAT OF SUBSTITUTES 30
5.2.5 INTENSITY OF RIVALRY 30
6 GLOBAL PEGYLATED DRUGS MARKET, BY MOLECULE
6.1 OVERVIEW 31
6.2 PROTEIN 33
6.3 FAB’ FRAGMENT 33
6.4 ENZYME 34
6.5 APTAMER 34
7 GLOBAL PEGYLATED DRUGS MARKET, BY INDICATION
7.1 OVERVIEW 35
7.2 CANCER 37
7.3 GOUT 37
7.4 HEMOPHILIA 38
7.5 HEPATITIS 38
8 GLOBAL PEGYLATED DRUGS MARKET, BY REGION
8.1 OVERVIEW 39
8.2 AMERICAs 41
8.2.1 NORTH AMERICA 43
8.2.2 LATIN AMERICA 45
8.3 EUROPE 46
8.3.1 WESTERN EUROPE 48
8.3.2 EASTERN EUROPE 55
8.4 ASIA-PACIFIC 56
8.4.1 JAPAN 58
8.4.2 CHINA 59
8.4.3 INDIA 60
8.4.4 AUSTRALIA 61
8.4.5 SOUTH KOREA 62
8.4.6 REST OF ASIA-PACIFIC 63
8.5 MIDDLE EAST & AFRICA 64
8.5.1 MIDDLE EAST 66
8.5.2 AFRICA 67
9 COMPETITIVE LANDSCAPE
9.1 INTRODUCTION 68
9.2 MAJOR PEGYLATED DRUGS 70
10 COMPANY PROFILES
10.1 HORIZON THERAPEUTICS PLC 71
10.1.1 COMPANY OVERVIEW 71
10.1.2 FINANCIAL OVERVIEW 71
10.1.3 PRODUCTS/SERVICES OFFERED 72
10.1.4 KEY DEVELOPMENTS 72
10.1.5 SWOT ANALYSIS 73
10.1.6 KEY STRATEGIES 73
10.2 F. HOFFMANN-LA ROCHE LTD 74
10.2.1 COMPANY OVERVIEW 74
10.2.2 FINANCIAL OVERVIEW 74
10.2.3 PRODUCTS/SERVICES OFFERED 75
10.2.4 KEY DEVELOPMENTS 75
10.2.5 SWOT ANALYSIS 75
10.2.6 KEY STRATEGIES 76
10.3 PFIZER INC. 77
10.3.1 COMPANY OVERVIEW 77
10.3.2 FINANCIAL OVERVIEW 77
10.3.3 PRODUCTS/SERVICES OFFERED 78
10.3.4 KEY DEVELOPMENTS 78
10.3.5 SWOT ANALYSIS 79
10.3.6 KEY STRATEGIES 79
10.4 NOVO NORDISK A/S 80
10.4.1 COMPANY OVERVIEW 80
10.4.2 FINANCIAL OVERVIEW 80
10.4.3 PRODUCTS/SERVICES OFFERED 81
10.4.4 KEY DEVELOPMENTS 81
10.4.5 SWOT ANALYSIS 82
10.4.6 KEY STRATEGIES 82
10.5 UCB S.A. 83
10.5.1 COMPANY OVERVIEW 83
10.5.2 FINANCIAL OVERVIEW 83
10.5.3 PRODUCTS/SERVICES OFFERED 84
10.5.4 KEY DEVELOPMENTS 84
10.5.5 SWOT ANALYSIS 85
10.5.6 KEY STRATEGIES 85
10.6 AMGEN, INC. 86
10.6.1 COMPANY OVERVIEW 86
10.6.2 FINANCIAL OVERVIEW 86
10.6.3 Products/Services Offered 87
10.6.4 KEY DEVELOPMENTS 87
10.6.5 KEY STRATEGIES 88
10.7 ASTRAZENECA 89
10.7.1 COMPANY OVERVIEW 89
10.7.2 FINANCIAL OVERVIEW 89
10.7.3 PRODUCTS/SERVICES OFFERED 90
10.7.4 KEY DEVELOPMENTS 90
10.7.5 SWOT ANALYSIS 90
10.7.6 KEY STRATEGIES 91
10.8 MERCK & CO., INC. 92
10.8.1 COMPANY OVERVIEW 92
10.8.2 FINANCIAL OVERVIEW 92
10.8.3 PRODUCTS/SERVICES OFFERED 93
10.8.4 KEY DEVELOPMENTS 93
10.8.5 SWOT ANALYSIS 94
10.8.6 KEY STRATEGIES 94
10.9 TAKEDA PHARMACEUTICAL COMPANY LIMITED 95
10.9.1 COMPANY OVERVIEW 95
10.9.2 FINANCIAL OVERVIEW 95
10.9.3 PRODUCTS/SERVICES OFFERED 96
10.9.4 KEY DEVELOPMENTS 96
10.9.5 SWOT ANALYSIS 96
10.9.6 KEY STRATEGIES 97
10.10 BAYER AG 98
10.10.1 COMPANY OVERVIEW 98
10.10.2 FINANCIAL OVERVIEW 98
10.10.3 PRODUCTS/SERVICES OFFERED 99
10.10.4 KEY DEVELOPMENTS 99
10.10.5 SWOT ANALYSIS 99
10.10.6 KEY STRATEGIES 100
11 APPENDIX
11.1 REFERENCES 101
11.2 RELATED REPORTS 101
